The Cyprus Institute of Neurology and Genetics (CING) has launched two new research programmes to improve the classification ...

By Dennis Thompson HealthDay ReporterFRIDAY, May 16, 2025 (HealthDay News) — Transmasculine and gender diverse people who use testosterone are not at an increased risk for cervical, ovarian or other ...

MSD has reported that the Phase III KEYNOTE-B96 trial of Keytruda plus paclitaxel, with or without bevacizumab, has met its ...

In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

A cancer survivor is raising awareness about the importance of genetic testing. Why she believes it can be imperative to ...

In this video, Ursula A. Matulonis, MD, discusses new data on rinatabart sesutecan, or Rina-S, for patients with advanced ovarian cancer, which were presented at Society of Gynecologic Oncology Annual ...

In this video, Ursula A. Matulonis, MD, discusses results from the phase 3 MIRASOL trial of mirvetuximab soravtansine-gynx for patients with folate receptor alpha-positive, platinum-resistant ovarian ...

The U.S. Federal Drug Administration (FDA) has granted Incyclix Bio Fast Track designation for INX-315 to treat ...

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies.

The early months of 2025 have seen a surge of research centered on cannabidiol (CBD), with studies investigating its role in ...